Combination targeted therapy with Janus kinase inhibition plus biologic agents in refractory JIA: an international multi-centre case series.

OBJECTIVES: To describe multi-centre real-world experience of combination targeted therapy (CTT) using a Janus kinase inhibitor (JAKi) and biologic in juvenile idiopathic arthritis (JIA). METHODS: Paediatric rheumatology centres across the United Kingdom and Republic of Ireland with experience of JAKi-biologic CTT use in JIA were identified. Written patient consent and local approval was obtained.Data on patient characteristics, treatment history, adverse events, and disease activity were collected by retrospective review of medical records. Paired data were analysed using Wilcoxon signed-rank test. RESULTS: 13 patients with JIA were identified (11 Still's disease/systemic; 1 psoriatic; 1 extended oligoarticular) across nine centres. Historical joint damage (39%) and glucocorticoid toxicity (77%) were common.Median 5 conventional/biologic/targeted synthetic DMARDs (IQR 4-7) were used over a median 66 months (IQR 36-133) before CTT initiation at median age 12 years (IQR 9-14). Tofacitinib-tocilizumab was the most frequent combination.CTT was used briefly as bridging therapy in 2/13, with 11/13 remaining on CTT for ≥12 months, permitting paired analysis at 12 months. A significant reduction in 12-month intravenous methylprednisolone exposure (median 109mg/kg vs. 0mg/kg; p=0.013) and active joint count (median 5 vs. 2 joints; p=0.009) was seen. At last follow-up (median 21.5 months), 6/10 still on CTT had inactive disease, with 8/10 off systemic steroids.No serious infections occurred. Two non-infectious serious adverse events were reported; hip avascular necrosis and pulmonary alveolar proteinosis. CONCLUSION: JAKi-biologic CTT may have a role in improving disease control in refractory JIA, enabling some reduction in glucocorticoids, with no serious infections reported.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-12
DOI
https://doi.org/10.1093/rheumatology/keag633
Primary Topic
Autoimmune and Inflammatory Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Combination targeted therapy with Janus kinase inhibition plus biologic agents in refractory JIA: an international multi-centre case series.

Lucy Paterson-Brown, Joshua L. Bennett, Barrak Almoosawi, Orla Geraldine Killeen et al.
PubMed
Autoimmune and Inflammatory Disorders Research
article

Combination targeted therapy with Janus kinase inhibition plus biologic agents in refractory JIA: an international multi-centre case series.

Lucy Paterson-Brown, Joshua L. Bennett, Barrak Almoosawi, Orla Geraldine Killeen, Samantha Cooray, Mark Wood, Nandita Pai, Elizabeth Twynam-Perkins, Rawan Almubarak, Octavio Aragon Cuevas, Jayne M. MacMahon, Irfan Nengroo, Marcus Sim, Joanne May, Jessica Fisher
article en

Abstract

OBJECTIVES: To describe multi-centre real-world experience of combination targeted therapy (CTT) using a Janus kinase inhibitor (JAKi) and biologic in juvenile idiopathic arthritis (JIA). METHODS: Paediatric rheumatology centres across the United Kingdom and Republic of Ireland with experience of JAKi-biologic CTT use in JIA were identified. Written patient consent and local approval was obtained.Data on patient characteristics, treatment history, adverse events, and disease activity were collected by retrospective review of medical records. Paired data were analysed using Wilcoxon signed-rank test. RESULTS: 13 patients with JIA were identified (11 Still's disease/systemic; 1 psoriatic; 1 extended oligoarticular) across nine centres. Historical joint damage (39%) and glucocorticoid toxicity (77%) were common.Median 5 conventional/biologic/targeted synthetic DMARDs (IQR 4-7) were used over a median 66 months (IQR 36-133) before CTT initiation at median age 12 years (IQR 9-14). Tofacitinib-tocilizumab was the most frequent combination.CTT was used briefly as bridging therapy in 2/13, with 11/13 remaining on CTT for ≥12 months, permitting paired analysis at 12 months. A significant reduction in 12-month intravenous methylprednisolone exposure (median 109mg/kg vs. 0mg/kg; p=0.013) and active joint count (median 5 vs. 2 joints; p=0.009) was seen. At last follow-up (median 21.5 months), 6/10 still on CTT had inactive disease, with 8/10 off systemic steroids.No serious infections occurred. Two non-infectious serious adverse events were reported; hip avascular necrosis and pulmonary alveolar proteinosis. CONCLUSION: JAKi-biologic CTT may have a role in improving disease control in refractory JIA, enabling some reduction in glucocorticoids, with no serious infections reported.

PubMed
Leeds General Infirmary (GB), Nottingham University Hospitals NHS Trust (GB), Great Ormond Street Hospital (GB), Royal Hospital for Children (GB), Children's Health Ireland at Crumlin (IE), Noah's Ark Children's Hospital for Wales (GB), Great North Children's Hospital (GB), Addenbrooke's Hospital (GB), Alder Hey Children's Hospital (GB)
Good health and well-being
Autoimmune and Inflammatory Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon